Financial Performance - Boston Scientific reported net sales of $4.209 billion for Q3 2024, a 19.4% increase on a reported basis compared to the prior year[2]. - GAAP net income attributable to common stockholders was $469 million, or $0.32 per share, down from $505 million or $0.34 per share a year ago; adjusted EPS was $0.63, up from $0.50[2]. - The company estimates full-year 2024 net sales growth of approximately 16.5% on a reported basis and adjusted EPS in the range of $2.45 to $2.47[9]. - For Q4 2024, net sales growth is expected to be between 16.5% to 18.5% on a reported basis, with adjusted EPS estimated between $0.64 to $0.66[10]. - Net sales for the three months ended September 30, 2024, were $4,209 million, a 19.3% increase from $3,527 million in the same period of 2023[16]. - Gross profit for the nine months ended September 30, 2024, was $8,395 million, up 14.8% from $7,317 million in the prior year[16]. - Operating income for the three months ended September 30, 2024, was $733 million, compared to $693 million for the same period in 2023, reflecting a 5.8% increase[16]. - Net income attributable to Boston Scientific common stockholders for the nine months ended September 30, 2024, was $1,288 million, compared to $1,065 million in the same period of 2023, representing a 20.9% increase[16]. - Non-GAAP adjusted net income for the three months ended September 30, 2024, was $1,082 million, compared to $734 million in the same period of 2023, a 47.3% increase[19]. - The diluted net income per share for the three months ended September 30, 2024, was $0.32, down from $0.34 in the same period of 2023[16]. - Adjusted net income attributable to Boston Scientific common stockholders was $2,181 million, resulting in an adjusted EPS of $1.50[20]. Sales Growth - The Cardiovascular segment achieved a reported net sales growth of 25.0%, while MedSurg grew by 10.3%[2]. - U.S. net sales increased by 23.5% to $2.593 billion, while EMEA and APAC regions saw growth of 15.2% and 12.1%, respectively[7]. - The company achieved organic net sales growth of 18.2% in Q3 2024, exceeding its guidance range of 13% to 15%[2]. - The company expects operational growth of approximately 17.0% for the full year 2024, with organic growth estimated at around 15.0%[21]. - The impact of acquisitions/divestitures on sales growth is projected to be a negative 2.0% for both Q4 2024 and the full year 2024[21]. - The effect of foreign currency fluctuations on reported growth is estimated at a negative 0.5% for Q4 2024[21]. Expenses and Costs - Research and development expenses for the three months ended September 30, 2024, were $407 million, an increase of 14.4% from $356 million in the same period of 2023[16]. - Operating expenses for the nine months ended September 30, 2024, totaled $6,467 million, an increase of 16.3% from $5,558 million in the prior year[19]. - Interest expense for the nine months ended September 30, 2024, was $225 million, compared to $200 million in the same period of 2023, reflecting a 12.5% increase[16]. - The company incurred $620 million in amortization expenses and $58 million in intangible asset impairment charges during the reporting period[20]. Product Development and Acquisitions - The company received FDA approval for the FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software for cardiac ablation procedures[3]. - Boston Scientific completed the acquisition of Silk Road Medical, Inc., enhancing its product offerings in stroke prevention[4]. - Boston Scientific's product pipeline and clinical evidence are expected to drive long-term momentum and growth[1].

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates. The company should continue to benefit fr ...

New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablationMARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW™ Software, which will combi ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast revenues of $4.03 billion, representing an increase of 14.4% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a co ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying BSX stock? Here’s what analysts think: Read More: ...

Boston Scientific (BSX) closed the most recent trading day at $87, moving +0.27% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.47%. On the other hand, the Dow registered a gain of 0.79%, and the technology-centric Nasdaq increased by 0.28%.Heading into today, shares of the medical device manufacturer had gained 5.15% over the past month, outpacing the Medical sector's loss of 4.27% and the S&P 500's gain of 3.48% in that time.The investment community wil ...

The market expects Boston Scientific (BSX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be ...

Boston Scientific Corporation (BSX) is scheduled to report third-quarter 2024 results on Oct. 23, before the opening bell.In the last reported quarter, the company’s earnings per share of 62 cents exceeded the Zacks Consensus Estimate by 6.9%. BSX’s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.18%, on average.Q3 EstimatesThe Zacks Consensus Estimate for third-quarter total revenues is pegged at $4.03 billion, suggestin ...

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 4.8% over the past month. The stock hit a new 52-week high of $87.79 in the previous session. Boston Scientific has gained 51.4% since the start of the year compared to the 8.6% move for the Zacks Medical sector and the 14.5% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our e ...

Company Performance - Boston Scientific (BSX) closed at $86.20, down 0.58% from the previous trading session, underperforming the S&P 500 which lost 0.21% [1] - Over the past month, BSX shares gained 4.53%, outperforming the Medical sector's decline of 3.28% but lagging behind the S&P 500's increase of 5.94% [1] - The upcoming earnings report on October 23, 2024, is projected to show earnings of $0.58 per share, reflecting a year-over-year growth of 16%, with revenue expected to be $4.03 billion, indicating a 14.36% increase [1] Earnings Estimates - The full-year Zacks Consensus Estimates for BSX are earnings of $2.40 per share and revenue of $16.26 billion, representing year-over-year changes of +17.07% and +14.22%, respectively [2] - Recent changes to analyst estimates suggest a favorable outlook on the company's business health and profitability [2] Valuation Metrics - Boston Scientific has a Zacks Rank of 2 (Buy), with the Zacks Consensus EPS estimate increasing by 0.07% in the past month [3] - The company has a Forward P/E ratio of 36.12, which is a premium compared to the industry's average Forward P/E of 24.88 [3] - BSX's PEG ratio stands at 2.87, compared to the Medical - Products industry's average PEG ratio of 1.92 [3] Industry Overview - The Medical - Products industry is part of the Medical sector and holds a Zacks Industry Rank of 69, placing it in the top 28% of over 250 industries [4] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]